ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

Hemophilia and Rare Bleeding Disorders » Hemophilia - Basic

Theme Navigation

  • ISTH 2022 Congress
    • Hemophilia and Rare Bleeding Disorders
      • Hemophilia - Basic

Abstract Number: OC 37.4

A humanized mouse model to assess the therapeutic potential of IdeS in hemophilia A with inhibitors

M. Bou Jaoudeh1, V. Daventure2, S. Delignat2, J. astermark3, H. Lévesque4, V. Proulle5, S. Lacroix-Desmazes6

Abstract Number: PB0174

Activated Factor XI as Activator of Thrombin Generation to Increase Assay Sensitivity

R. Arisz1, T. van Lienden2, R. de Laat-Kremers3, J. Eikenboom4, S. Schols5, M. de Maat6

Abstract Number: VPB0204

Association between platelet receptor genotypes and the bleeding tendency of hemophilia patients

L. Bury1, H. Kuchi Bhotla2, G. Piroli2, E. Cesari2, E. Falcinelli2, G. Guglielmini2, R. De Cristofaro3, B. Zieger4, P. Gresele2

Abstract Number: PB0181

Bleeding according to FVIII activity in 641 children with non-severe haemophilia – data from the PedNet study group

M. de Kovel1, C. Königs2, S. Ranta3, C. Escuriola Ettingshausen4, K. Fischer5

Abstract Number: OC 70.5

Bleeding in non-severe haemophilia A and B – data from the PedNet study group.

M. de Kovel1, C. Königs2, S. Ranta3, C. Escuriola Ettingshausen4, K. Fischer5

Abstract Number: PB0192

Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan

A. Amirah1, I. Palau2, A. Rosli1, N. Allie2

Abstract Number: PB0199

Budget impact of increasing rVIII-SingleChain use in patients in Italy with moderate and severe hemophilia A

S. Yan1, R. Tomic2, M. Panebianco2, E. Dlotko3, L. Stern3, R. Marino4

Abstract Number: VPB0206

Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan

N. Matsumoto1, H. Abe1, R. Kawasaki1, Y. Tashiro1, M. Noguchi1, S. Harada1, K. Yoneyama2, T. Niino2, T. Soeda1, Y. Yoshimura1

Abstract Number: VPB0208

Coagulant potential of emicizumab in child hemophilia A patients

M. Takeyama1, N. Matsumoto2, H. Abe2, S. Harada2, K. Ogiwara3, S. Furukawa3, T. Soeda2, K. Nogami1

Abstract Number: PB0177

Detection of IgG4 anti-FVIII levels as complementary test to define the ITI outcome in patients with hemophilia A: results from the BrazIT Study

D. Chaves1, B. Ayala2, R. Camelo3, L. Etto4, A. De Oliveira5, V. Franco6, M. Roberti7, R. Ribeiro8, M. De Cerqueira9, F. Callado10, T. Anegawa11, M. Cerqueira12, S. Rezende2

Abstract Number: OC 50.4

Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice

T. SEFIANE1, V. Muczynski2, X. Heiligenstein3, O. Christophe2, C. Denis2, C. Casari4, P. Lenting2

Abstract Number: PB0191

DNA extracellular traps as potential biomarker of chronic haemophilic synovitis and therapeutic perspective in patients treated with PRP

P. Oneto1, M. Landro2, C. Daffunchio2, A. Douglas Price3, E. Carrera SIlva1, H. Caviglia2, J. Etulain4

Abstract Number: PB0193

Dose optimization for prophylaxis using a pharmacokinetic model for factor IX products in severe hemophilia B

B. Vandewalle1, G. Castaman2, M. Alvarez-Román3, C. Escuriola Ettingshausen4, L. Nemes5, R. Tomic6, P. Martins1, J. Rodrigues7, K. Pinachyan8

Abstract Number: OC 30.2

Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Real-life-data documented by eDiary smart medication

W. Mondorf1, E. Hermann2, C. Escuriola Ettingshausen3, F. Ronald4, K. Holstein5, R. Klamroth6, U. Sachs7

Abstract Number: PB0179

Establishment of a monolayer-based LSEC-like endothelial cell in vitro system from induced pluripotent stem cells

P. Chawla1, M. Rath2, J. Oldenburg3, H. Singer4

Abstract Number: PB0185

Exploring red blood cells as a novel tolerogenic approach for factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II

M. Miranda1, E. Brandsma2, P. Kaijen1, F. van Alphen3, R. van Bruggen4, K. Fijnvandraat5, S. Lacroix-Desmazes6, J. Voorberg1

Abstract Number: OC 07.4

Exploring the conformational landscape of Factor VIII B domain in order to generate an all atom full length structure of the coagulation Factor VIII protein

S. Ramaraje Urs1, S. Singh2, H. Javed3, D. Fenel4, J. Teulon5, G. Schoehn5, J. Pellequer5, B. Ma6, D. Ugurlar6, D. Imhof7, J. Oldenburg8, A. Biswas1

Abstract Number: VPB0207

Factor VIII K1813A has high affinity for activated factor IX and enhances global coagulation function

Y. Nakajima1, M. Takeyama2, A. Oda3, K. Nogami2

Abstract Number: PB0187

FIX binding to collagen IV generates thrombin via the extrinsic tenase

G. Morrow1, M. Laffan2, N. Curry3

Abstract Number: OC 37.2

Follicular regulatory T cells promote anti-FVIII inhibitor development in hemophilia A mice

W. Jing1, J. Chen1, Y. Cai1, J. Schroeder1, A. Dent2, Q. Shi1

  • 1
  • 2
  • 3
  • Next Page »

« View all themes from the ISTH 2022 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2022 John Wiley & Sons, Inc. All Rights Reserved.
Wiley